AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway

Author:

Liu ChenORCID,Huang Yuhan,Qin Tianyu,You Lixin,Lu Funian,Hu Dianxing,Xiao Rourou,Qin Xu,Guo Ensong,Yang Bin,Li Xi,Fan Junpeng,Li Xiong,Fu Yu,Liu Si,Wang Zhuozi,Dou Yingyu,Wang Wei,Li Wenting,Yang Xiaohang,Liu Jingbo,Peng Wenju,Zhang Li,Cui Yaoyuan,Sun Chaoyang,Chen Gang

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. Ovarian Cancer Population Screening and Mortality after Long-Term Follow-Up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a Randomised Controlled Trial;Menon,2021

2. Treatment of epithelial ovarian cancer;Kuroki;BMJ,2020

3. Treating cancer with selective CDK4/6 inhibitors;O'Leary;Nat. Rev. Clin. Oncol.,2016

4. Targeting CDK4 and CDK6: from discovery to therapy;Sherr;Cancer Discov.,2016

5. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer;Zhou;Cancer Lett.,2017

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3